Netu-palo-FDC (NEPA)

Company	Helsinn Healthcare S.A.
Description	Fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist
Molecular Target	Neurokinin 1 (NK1) Substance P receptor (TACR1) ; Serotonin (5-HT3) receptor
Mechanism of Action	Neurokinin-1 (NK-1) (Substance P) receptor antagonist; Serotonin (5-HT3) receptor antagonist

Latest Stage of Development	Phase III
Indication	Emesis
Partner	Eisai Co. Ltd.; Galenica Ltd.; Riemser Arzneimittel AG; Taiho Pharmaceutical Co. Ltd.

Product Details